1.Clinical Outcome of Nunchaku-Style Silicone Tube Intubation in Patients with Nasolacrimal Duct Obstruction
Jee Hyeon OH ; Hyun Young PARK ; Jin Sook YOON ; Jaesang KO
Journal of the Korean Ophthalmological Society 2026;67(1):1-8
Purpose:
This study evaluated the long-term clinical outcomes of silicone tube intubation using a Nunchaku® (FCI Ophthalmics Inc., Pembroke, MA, USA) tube in adult patients with epiphora.
Methods:
A prospective study was conducted on 42 eyes in 32 patients who underwent silicone tube intubation with a Nunchaku® tube between March 2023 and September 2023. Clinical manifestations, Munk scale scores, lacrimal syringing test results, and tear meniscus height were assessed before and after surgery. Surgical success was defined as a Munk score of ≤ 1.
Results:
The mean age of the participants was 56.2 years. Preoperative lacrimal irrigation testing revealed partial obstruction in 29 eyes (69.0%), patent passage in 11 eyes (26.2%), and punctal stenosis in 2 eyes (4.76%). The mean operative time was 6.4 minutes for monocular procedures and 9.7 minutes for binocular procedures. At three months postoperatively, 33 eyes (78.6%) in 28 patients achieved a Munk scale score of ≤ 1. No significant differences were observed between the surgical success and failure groups in terms of preoperative Munk scale scores, lacrimal syringing test results, or tear meniscus height. One patient who underwent binocular surgery experienced worsening symptoms in both eyes postoperatively with associated punctal inflammation and granuloma formation necessitating early silicone tube removal. Slit punctum was observed in 17 eyes across 11 patients, six of whom underwent a snip procedure during surgery.
Conclusions
Silicone tube intubation using the Nunchaku-style tube is a relatively simple and effective treatment for nasolacrimal duct obstruction. However, an increased incidence of lacrimal punctum-related complications was observed compared to previous studies, indicating the need for caution when performing the snip procedure concurrently.
2.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
3.Comparison of Population Attributable Fractions of Cancer Incidence and Mortality Linked to Excess Body Weight in Korea from 2015 to 2030
Youjin HONG ; Jihye AN ; Jeehi JUNG ; Hyeon Sook LEE ; Soseul SUNG ; Sungji MOON ; Inah KIM ; Jung Eun LEE ; Aesun SHIN ; Sun Ha JEE ; Sun-Seog KWEON ; Min-Ho SHIN ; Sangmin PARK ; Seung-Ho RYU ; Sun Young YANG ; Seung Ho CHOI ; Jeongseon KIM ; Sang-Wook YI ; Yoon-Jung CHOI ; Sangjun LEE ; Woojin LIM ; Kyungsik KIM ; Sohee PARK ; Jeong-Soo IM ; Hong Gwan SEO ; Kwang-Pil KO ; Sue K. PARK
Endocrinology and Metabolism 2024;39(6):921-931
Background:
The increasing rate of excess body weight (EBW) in the global population has led to growing health concerns, including cancer-related EBW. We aimed to estimate the population attributable fraction (PAF) of cancer incidence and deaths linked to EBW in Korean individuals from 2015 to 2030 and to compare its value with various body mass index cutoffs.
Methods:
Levin’s formula was used to calculate the PAF; the prevalence rates were computed using the Korean National Health and Nutrition Examination Survey data, while the relative risks of specific cancers related to EBW were estimated based on the results of Korean cohort studies. To account for the 15-year latency period when estimating the PAF in 2020, the prevalence rates from 2015 and attributable cases or deaths from 2020 were used.
Results:
The PAF attributed to EBW was similar for both cancer incidence and deaths using either the World Health Organization (WHO) Asian-Pacific region standard or a modified Asian standard, with the WHO standard yielding the lowest values. In the Korean population, the PAFs of EBW for cancer incidence were 2.96% in men and 3.61% in women, while those for cancer deaths were 0.67% in men and 3.06% in women in 2020. Additionally, PAFs showed a gradual increase in both sexes until 2030.
Conclusion
The EBW continues to have a significant impact on cancer incidence and deaths in Korea. Effective prevention strategies targeting the reduction of this modifiable risk factor can substantially decrease the cancer burden.
4.Comparison of Population Attributable Fractions of Cancer Incidence and Mortality Linked to Excess Body Weight in Korea from 2015 to 2030
Youjin HONG ; Jihye AN ; Jeehi JUNG ; Hyeon Sook LEE ; Soseul SUNG ; Sungji MOON ; Inah KIM ; Jung Eun LEE ; Aesun SHIN ; Sun Ha JEE ; Sun-Seog KWEON ; Min-Ho SHIN ; Sangmin PARK ; Seung-Ho RYU ; Sun Young YANG ; Seung Ho CHOI ; Jeongseon KIM ; Sang-Wook YI ; Yoon-Jung CHOI ; Sangjun LEE ; Woojin LIM ; Kyungsik KIM ; Sohee PARK ; Jeong-Soo IM ; Hong Gwan SEO ; Kwang-Pil KO ; Sue K. PARK
Endocrinology and Metabolism 2024;39(6):921-931
Background:
The increasing rate of excess body weight (EBW) in the global population has led to growing health concerns, including cancer-related EBW. We aimed to estimate the population attributable fraction (PAF) of cancer incidence and deaths linked to EBW in Korean individuals from 2015 to 2030 and to compare its value with various body mass index cutoffs.
Methods:
Levin’s formula was used to calculate the PAF; the prevalence rates were computed using the Korean National Health and Nutrition Examination Survey data, while the relative risks of specific cancers related to EBW were estimated based on the results of Korean cohort studies. To account for the 15-year latency period when estimating the PAF in 2020, the prevalence rates from 2015 and attributable cases or deaths from 2020 were used.
Results:
The PAF attributed to EBW was similar for both cancer incidence and deaths using either the World Health Organization (WHO) Asian-Pacific region standard or a modified Asian standard, with the WHO standard yielding the lowest values. In the Korean population, the PAFs of EBW for cancer incidence were 2.96% in men and 3.61% in women, while those for cancer deaths were 0.67% in men and 3.06% in women in 2020. Additionally, PAFs showed a gradual increase in both sexes until 2030.
Conclusion
The EBW continues to have a significant impact on cancer incidence and deaths in Korea. Effective prevention strategies targeting the reduction of this modifiable risk factor can substantially decrease the cancer burden.
5.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
6.Comparison of Population Attributable Fractions of Cancer Incidence and Mortality Linked to Excess Body Weight in Korea from 2015 to 2030
Youjin HONG ; Jihye AN ; Jeehi JUNG ; Hyeon Sook LEE ; Soseul SUNG ; Sungji MOON ; Inah KIM ; Jung Eun LEE ; Aesun SHIN ; Sun Ha JEE ; Sun-Seog KWEON ; Min-Ho SHIN ; Sangmin PARK ; Seung-Ho RYU ; Sun Young YANG ; Seung Ho CHOI ; Jeongseon KIM ; Sang-Wook YI ; Yoon-Jung CHOI ; Sangjun LEE ; Woojin LIM ; Kyungsik KIM ; Sohee PARK ; Jeong-Soo IM ; Hong Gwan SEO ; Kwang-Pil KO ; Sue K. PARK
Endocrinology and Metabolism 2024;39(6):921-931
Background:
The increasing rate of excess body weight (EBW) in the global population has led to growing health concerns, including cancer-related EBW. We aimed to estimate the population attributable fraction (PAF) of cancer incidence and deaths linked to EBW in Korean individuals from 2015 to 2030 and to compare its value with various body mass index cutoffs.
Methods:
Levin’s formula was used to calculate the PAF; the prevalence rates were computed using the Korean National Health and Nutrition Examination Survey data, while the relative risks of specific cancers related to EBW were estimated based on the results of Korean cohort studies. To account for the 15-year latency period when estimating the PAF in 2020, the prevalence rates from 2015 and attributable cases or deaths from 2020 were used.
Results:
The PAF attributed to EBW was similar for both cancer incidence and deaths using either the World Health Organization (WHO) Asian-Pacific region standard or a modified Asian standard, with the WHO standard yielding the lowest values. In the Korean population, the PAFs of EBW for cancer incidence were 2.96% in men and 3.61% in women, while those for cancer deaths were 0.67% in men and 3.06% in women in 2020. Additionally, PAFs showed a gradual increase in both sexes until 2030.
Conclusion
The EBW continues to have a significant impact on cancer incidence and deaths in Korea. Effective prevention strategies targeting the reduction of this modifiable risk factor can substantially decrease the cancer burden.
7.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
8.Implementation of Pharmaceutical Care Services During the COVID-19 Pandemic Worldwide
So Yeon LEE ; Seunghyun CHEON ; Hye Won PARK ; Sang Hyeon OH ; Jee-Eun CHUNG ; Sook Hee AN
Korean Journal of Clinical Pharmacy 2024;34(4):242-251
Background:
This study sought to research the implementation of pharmaceutical care services and review the pharmaceutical care services used for coronavirus disease 2019 (COVID-19) prevention, diagnosis, therapy, and vaccination during the COVID-19 pandemic.
Methods:
All articles reporting pharmacists’ implementation of pharmaceutical care services during the COVID-19 pandemic were comprehensively searched in PubMed/Medline, Embase, and the Cochrane Library databases up toJuly 7, 2021, then included in this study. Twenty-four items of pharmaceutical care services were classified into the following 5categories: patient evaluation and monitoring, clinical decision support, compounding/dispensing/administration, patient consultation and education, and drug-related policy research and development.
Results:
A total of 674 articles from 100 countrieswere included, with the United States of America being the most frequently studied country. Across the 5 classified categories,compounding/dispensing/administration was most frequently examined (28.9%), followed by patient consultation and education (25.2%). Among the 24 items of pharmaceutical care services, medicine supply management was most frequently reported on (11.4%), followed by patient consultations (11.0%). The primary implemented pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination were public health education, COVID-19 testing services, medicine supply management, and vaccination, respectively.
Conclusion
Pharmacists have implemented diverse pharmaceutical care services for COVID-19 prevention, diagnosis, therapy, and vaccination globally. Further studies should be conducted to determine the correlation between the characteristics of healthcare accessibility in a country and the implemented pharmaceutical care services for COVID-19.
9.Comparison of Population Attributable Fractions of Cancer Incidence and Mortality Linked to Excess Body Weight in Korea from 2015 to 2030
Youjin HONG ; Jihye AN ; Jeehi JUNG ; Hyeon Sook LEE ; Soseul SUNG ; Sungji MOON ; Inah KIM ; Jung Eun LEE ; Aesun SHIN ; Sun Ha JEE ; Sun-Seog KWEON ; Min-Ho SHIN ; Sangmin PARK ; Seung-Ho RYU ; Sun Young YANG ; Seung Ho CHOI ; Jeongseon KIM ; Sang-Wook YI ; Yoon-Jung CHOI ; Sangjun LEE ; Woojin LIM ; Kyungsik KIM ; Sohee PARK ; Jeong-Soo IM ; Hong Gwan SEO ; Kwang-Pil KO ; Sue K. PARK
Endocrinology and Metabolism 2024;39(6):921-931
Background:
The increasing rate of excess body weight (EBW) in the global population has led to growing health concerns, including cancer-related EBW. We aimed to estimate the population attributable fraction (PAF) of cancer incidence and deaths linked to EBW in Korean individuals from 2015 to 2030 and to compare its value with various body mass index cutoffs.
Methods:
Levin’s formula was used to calculate the PAF; the prevalence rates were computed using the Korean National Health and Nutrition Examination Survey data, while the relative risks of specific cancers related to EBW were estimated based on the results of Korean cohort studies. To account for the 15-year latency period when estimating the PAF in 2020, the prevalence rates from 2015 and attributable cases or deaths from 2020 were used.
Results:
The PAF attributed to EBW was similar for both cancer incidence and deaths using either the World Health Organization (WHO) Asian-Pacific region standard or a modified Asian standard, with the WHO standard yielding the lowest values. In the Korean population, the PAFs of EBW for cancer incidence were 2.96% in men and 3.61% in women, while those for cancer deaths were 0.67% in men and 3.06% in women in 2020. Additionally, PAFs showed a gradual increase in both sexes until 2030.
Conclusion
The EBW continues to have a significant impact on cancer incidence and deaths in Korea. Effective prevention strategies targeting the reduction of this modifiable risk factor can substantially decrease the cancer burden.
10.Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han KIM ; In-Ho KIM ; Seung Joo KANG ; Miyoung CHOI ; Baek-Hui KIM ; Bang Wool EOM ; Bum Jun KIM ; Byung-Hoon MIN ; Chang In CHOI ; Cheol Min SHIN ; Chung Hyun TAE ; Chung sik GONG ; Dong Jin KIM ; Arthur Eung-Hyuck CHO ; Eun Jeong GONG ; Geum Jong SONG ; Hyeon-Su IM ; Hye Seong AHN ; Hyun LIM ; Hyung-Don KIM ; Jae-Joon KIM ; Jeong Il YU ; Jeong Won LEE ; Ji Yeon PARK ; Jwa Hoon KIM ; Kyoung Doo SONG ; Minkyu JUNG ; Mi Ran JUNG ; Sang-Yong SON ; Shin-Hoo PARK ; Soo Jin KIM ; Sung Hak LEE ; Tae-Yong KIM ; Woo Kyun BAE ; Woong Sub KOOM ; Yeseob JEE ; Yoo Min KIM ; Yoonjin KWAK ; Young Suk PARK ; Hye Sook HAN ; Su Youn NAM ; Seong-Ho KONG ;
Journal of Gastric Cancer 2023;23(1):3-106
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.

Result Analysis
Print
Save
E-mail